Phase 1a

Bio-Pharma

Octant Doses First Patient in Phase 1b/2 OCT-980 Study

EMERYVILLE, Calif. — September 24, 2026 Octant, Inc. announced that the first patient has been dosed in the Phase...

By cGxPwire Editor
September 25, 2026

Bio-Pharma

Sensorium Reports Positive Phase 1a Data for SNTX-2643

Cambridge, Massachusetts, U.S., September 21, 2026 Sensorium Therapeutics, a clinical-stage central nervous system biotechnology company, has announced positive Phase...

By cGxPwire Editor
September 23, 2026

Bio-Pharma

CRISPR Therapeutics Reports Durable CTX310 Lipid Lowering

Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...

By cGxPwire Editor
August 31, 2026

Bio-Pharma

Leads Biolabs’ Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051

NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...

By cGxPwire Editor
August 6, 2026

Bio-Pharma

ProMIS Reports First Human PMN310 Evidence

CAMBRIDGE, Mass., July 14, 2026 ProMIS Neurosciences presented the first human evidence that its investigational Alzheimer’s disease therapy PMN310...